MedPath

Efficacy of oral tranexamic acid and topical triple combination cream in treatment of melasma

Phase 4
Conditions
Health Condition 1: L814- Other melanin hyperpigmentation
Registration Number
CTRI/2024/04/065382
Lead Sponsor
MOHAN H
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients willing to give informed consent

2. Patients of either gender aged more than 18 years

3. Patients willing for follow up

4. Patients with clinically diagnosed melasma

Exclusion Criteria

1. Patient not willing to give informed consent

2. Patient already on melasma treatment with topical therapy within 2 weeks.

3. Pregnant and lactating females.

4. History of coexisting endocrinopathies.

5. History of thrombosis, thromboembolic episodes and altered blood coagulation profile.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in melasma area and severity indexTimepoint: Change in melasma area and severity index at 4 weeks and 8 weeks
Secondary Outcome Measures
NameTimeMethod
Safety and tolerability parameters of study medicationsTimepoint: At 4 weeks and 8 weeks
© Copyright 2025. All Rights Reserved by MedPath